OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Key Ophthalmic Conferences
TipRanks (Tue, 29-Sep 7:27 AM ET)
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
Globe Newswire (Tue, 28-Jul 7:00 AM ET)
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
Globe Newswire (Mon, 27-Jul 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Director
Globe Newswire (Thu, 23-Jul 12:00 PM ET)
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
Globe Newswire (Thu, 23-Jul 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
Globe Newswire (Wed, 22-Jul 10:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
Globe Newswire (Wed, 22-Jul 7:00 AM ET)
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Okyo Pharma Limited - trades on the NASDAQ stock market under the symbol OKYO.
As of October 2, 2026, OKYO stock price was flat at $1.34 with 1,128 million shares trading.
OKYO has a beta of 1.36, meaning it tends to be more sensitive to market movements. OKYO has a correlation of 0.08 to the broad based SPY ETF.
OKYO has a market cap of $70.32 million. This is considered a Micro Cap stock.
In the last 3 years, OKYO traded as high as $3.35 and as low as $.81.
OKYO has underperformed the market in the last year with a return of -33.3%, while the SPY ETF gained +16.3%. In the last 3 month period, OKYO fell short of the market, returning -10.7%, while SPY returned +3.4%. However, in the most recent 2 weeks OKYO has outperformed the stock market by returning +1.5%, while SPY returned +1.4%.
OKYO support price is $1.27 and resistance is $1.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKYO shares will trade within this expected range on the day.